financetom
Business
financetom
/
Business
/
Polestar to make new SUV in Europe from 2028
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Polestar to make new SUV in Europe from 2028
Jul 3, 2025 2:34 AM

STOCKHOLM, July 3 (Reuters) - Polestar said on

Thursday it would make its Polestar 7 SUV model at a Volvo Cars

factory in Slovakia, as the EV maker shifts more

production from China and tries to cut its exposure to heavy

European and U.S. tariffs.

Polestar said the two Swedish companies, both controlled by

China's Geely and its owner Li Shufu, had signed a

memorandum of understanding and the new model would launch in

2028.

"Polestar is taking the next step in diversifying its

contract manufacturing footprint by expanding it to Europe," the

company said.

Volvo's Kosice factory in Slovakia is scheduled to start

production in 2026, with an expected annual capacity of 250,000

cars.

Polestar, which has yet to make a profit, faces tariffs of

28.8% for the cars it brings into Europe and more than 100% for

any it imports into the United States.

The European Union imposed tariffs on Chinese-made EVs last

year because of what it describes as unfair subsidies from the

Chinese government. Beijing refutes this criticism.

Tariffs have impacted Polestar more than most European

automakers because the majority of its cars are produced in

China, either by Volvo Cars or Geely.

The automaker now produces some Polestar 3 SUVs in the

United States at a Volvo Cars plant in South Carolina.

Earlier this year, the company stopped taking new orders

from U.S. customers for the Polestar 2, which is still made in

China.

The automaker will also export the Polestar 4 to the United

States from a South Korean plant, where production is set to

begin in the second half of the year.

Earlier this year, Polestar said it would take longer to

become profitable and delayed its expansion of sales to

additional countries.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved